Previous 10 | Next 10 |
2024-02-21 10:00:32 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 20...
2024-02-19 08:02:11 ET Vaccinex Inc (VCNX) announced stock split at a ratio of 1-for-14 on 2024-02-20 ... Full story available on KlickAnalytics.com
2024-02-07 08:19:14 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex prices $3.7M PIPE financing
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammat...
2024-01-10 17:37:03 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex files to sell 712,484 shares for holders
2023-12-04 11:25:49 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex says Nasdaq gives co extension to regain compliance with listing rule
Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a cl...
2023-11-13 17:30:47 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex GAAP EPS of -$1.09, revenue of $0.02M
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GL...
News, Short Squeeze, Breakout and More Instantly...
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...